
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Lexeo Therapeutics, Inc. Common Stock (LXEO)


- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: LXEO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $19.78
1 Year Target Price $19.78
4 | Strong Buy |
3 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.75% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 641.95M USD | Price to earnings Ratio - | 1Y Target Price 19.78 |
Price to earnings Ratio - | 1Y Target Price 19.78 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.45 - 10.16 | Updated Date 10/21/2025 |
52 Weeks Range 1.45 - 10.16 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.91% | Return on Equity (TTM) -75.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 237828133 | Price to Sales(TTM) - |
Enterprise Value 237828133 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 416.34 | Enterprise Value to EBITDA -6.02 | Shares Outstanding 69626214 | Shares Floating 29333001 |
Shares Outstanding 69626214 | Shares Floating 29333001 | ||
Percent Insiders 0.5 | Percent Institutions 89.44 |
Upturn AI SWOT
Lexeo Therapeutics, Inc. Common Stock

Company Overview
History and Background
Lexeo Therapeutics is a clinical-stage gene therapy company focused on developing treatments for genetically defined cardiovascular and central nervous system diseases. Founded in 2021, it has rapidly advanced several programs into clinical trials.
Core Business Areas
- Cardiovascular Gene Therapy: Developing gene therapy candidates for genetic cardiomyopathies such as dilated cardiomyopathy (DCM).
- Central Nervous System (CNS) Gene Therapy: Developing gene therapy candidates for neurodegenerative diseases, including Alzheimer's disease.
Leadership and Structure
The leadership team includes experienced biotechnology executives and scientific advisors. The company operates with a focus on research and development, clinical trials, and regulatory approval.
Top Products and Market Share
Key Offerings
- LX2006 (DCM treatment): A gene therapy candidate for dilated cardiomyopathy caused by mutations in the LMNA gene. Phase 1/2 clinical trials are underway. Competitors include pharmaceutical companies developing traditional drug therapies for heart failure, as well as other gene therapy companies targeting cardiovascular diseases.
- LX1001 (Alzheimer's treatment): A gene therapy candidate targeting APOE2 for the treatment of Alzheimer's disease. Phase 1/2 clinical trials are underway. Competitors include companies developing anti-amyloid antibodies (e.g., Biogen, Eli Lilly) and other Alzheimer's disease therapeutics.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing success in clinical trials. The market is characterized by high development costs, regulatory hurdles, and significant unmet medical needs.
Positioning
Lexeo Therapeutics is positioned as a leader in developing gene therapies for cardiovascular and CNS diseases, focusing on genetically defined patient populations. Its competitive advantage lies in its proprietary gene therapy platform and experienced team.
Total Addressable Market (TAM)
The total addressable market for gene therapies in cardiovascular and CNS diseases is estimated to be in the billions of dollars. Lexeo is positioned to capture a significant share of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform
- Experienced leadership team
- Strong pipeline of clinical-stage programs
- Focus on genetically defined patient populations
- Strategic partnerships with leading academic institutions
Weaknesses
- High development costs
- Regulatory hurdles
- Clinical trial risks
- Dependence on external funding
- Limited commercialization experience
Opportunities
- Expansion of pipeline into new therapeutic areas
- Strategic partnerships with pharmaceutical companies
- Accelerated regulatory pathways for gene therapies
- Increasing prevalence of genetic diseases
- Positive clinical trial data
Threats
- Competition from established pharmaceutical companies
- Adverse clinical trial outcomes
- Regulatory setbacks
- Manufacturing challenges
- Ethical concerns surrounding gene therapy
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
- VIR
Competitive Landscape
Lexeo faces competition from established pharmaceutical companies and other gene therapy developers. Its competitive advantage lies in its specific focus on genetically defined cardiovascular and CNS diseases and its proprietary gene therapy platform. The market share is estimated since LXEO is a small cap and does not hold as much market share as other competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to the advancement of clinical programs and fundraising activities.
Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercialization of gene therapy products. Analyst estimates vary based on the perceived risk and potential of the company's pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for LX2006 and LX1001, expanding the pipeline with new gene therapy candidates, and securing strategic partnerships.
Summary
Lexeo Therapeutics is a clinical-stage gene therapy company with a promising pipeline targeting significant unmet medical needs. The company's success hinges on positive clinical trial outcomes and regulatory approvals. High development costs and competition present challenges. Lexeo's targeted approach to genetically defined diseases could provide a competitive advantage if they can deliver strong efficacy results and have good safety profiles for their treatments. It is still an early stage company with much risk and high reward potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexeo Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-11-03 | CEO & Director Mr. R. Nolan Townsend | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.lexeotx.com |
Full time employees 61 | Website https://www.lexeotx.com |
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.